Comparison of higher clopidogrel loading and maintenance dose to standard dose on platelet function and outcomes...

Area of Science:

• Cardiology
• Pharmacology
• Interventional Cardiology

Background:

• Optimal antiplatelet therapy is crucial for successful percutaneous coronary intervention (PCI) outcomes.
• Clopidogrel is a key antiplatelet agent used in PCI patients.

Purpose of the Study:

• To evaluate if a high-dose clopidogrel regimen is superior to standard dosing in patients undergoing PCI.
• To assess the impact of high-dose clopidogrel on platelet inhibition and clinical outcomes.

Main Methods:

• 119 patients undergoing PCI were randomized to high-dose (600 mg loading, 75 mg BID) or standard-dose (300 mg loading, 75 mg QD) clopidogrel for 1 month.
• Platelet aggregation was measured using light transmission aggregometry at baseline, 4 hours, and 30 days.
• Composite endpoints of cardiovascular death, myocardial infarction, target vessel revascularization, and bleeding were assessed at 30 days.

Main Results:

• High-dose clopidogrel achieved significantly greater platelet inhibition at 4 hours (41% vs 19%) and 30 days (27% vs 10%) compared to standard dosing (p < 0.05).
• The composite clinical endpoint occurred less frequently in the high-dose group (10.3% vs 23.8%, p = 0.04).
• No significant differences in major or minor bleeding events were observed between the groups.

Conclusions:

• A higher loading and maintenance dose of clopidogrel enhances platelet inhibition in PCI patients.
• This intensified regimen leads to a reduction in adverse cardiovascular events without an increase in bleeding risk.
• High-dose clopidogrel represents a potentially superior antiplatelet strategy for patients undergoing PCI.